© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Edited T cells survive and thrive in three patients in the first U.S. trial using this approach.
I’m teaming up with my buddy Kenny Capps for a cool podcast on everything thing myeloma.
Study focused on people who have exhausted available therapies but want to continue with treatment.
Yolanda Brunson-Sarrabo, CPT, NASM, is the author of “Another Face of Multiple Myeloma.”
90% to 100% of study participants achieved complete or partial responses to treatment.
A $4 million grant funds bench-to-bedside research to enhance immune-boosting power of autologous blood stem cell transplantation.
In a clinical trial, the research team is hoping to learn more about how myeloma cells resist CAR T-cell therapy.
Engineered immune cells get a helping hand in a new clinical trial for multiple myeloma patients.
The approval is based on data from CASSIOPEIA, an open-label, randomized, active-controlled phase 3 study.
September was designated as National Blood Cancer Awareness Month in 2010 by United States Congress.
The Affordable Care Act erases racial disparities in care for advanced cancers.
Even cancer that doesn’t affect the bones directly can contribute to bone problems.
“What was unique in this study was that in the VA, everybody is equal, and everyone gets the same access to drugs.”
Investigators say their findings support annual blood tests for all individuals with MGUS.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
